News | December 06, 2010

Blood Vessel Dysfunction Linked to Heart Disease Also Impacts Alzheimer's


December 6, 2010 - A blood vessel dysfunction that is linked to cardiovascular illness also appears to play a role in the development of Alzheimer's disease. Supporting data from the study was published in Circulation Research: Journal of the American Heart Association.

Alzheimer's disease typically affects people age 60 and older, depriving them of memory, reasoning and other cognitive skills.

Two distinct anomalies in the brain are hallmarks of Alzheimer's: neurofibrillary tangles, twisted fibers composed primarily of a protein called tau that arise inside neurons; and amyloid plaques, a buildup between neurons of protein fragments called amyloid beta peptides.

Previous research has found that people with multiple cardiovascular risk factors are also at greater risk for Alzheimer's. A central feature of those cardiovascular risk factors is a nitric oxide deficiency in the endothelium, the layer of cells lining the blood vessels. Nitric oxide is crucial in vasodilation - the widening of blood vessels - which improves blood flow and the delivery of oxygen and nutrients to surrounding tissue.

"If you look at any risk factor for cardiovascular disease - the standard risk factors like high cholesterol, diabetes, hypertension, smoking, sedentary lifestyle, aging - all of these have been associated with loss of nitric oxide in the endothelium, a condition known as endothelial dysfunction," said Zvonimir S. Katusic, M.D., Ph.D., senior author of the study and a professor of anesthesiology and pharmacology at the Mayo Clinic in Rochester, Minn.

In the study, the researchers tested whether endothelial dysfunction also plays a role in Alzheimer's disease. Using endothelial cells from microscopic blood vessels in the human brain, the scientists chemically inhibited eNOS (endothelial nitric oxide synthase), an enzyme involved in nitric oxide production.

Inhibiting eNOS triggered a series of biochemical effects that led to an increase in the production of amyloid precursor protein (APP). APP is the raw material for the plaques seen in the brains of Alzheimer's patients.

The quantity and activity of BACE1 also increased. BACE1 is an enzyme that cleaves APP to create the amyloid beta peptides that make up the plaques.

"Once you lose that basal nitric oxide, you see the increases in APP and BACE1, and the increase in amyloid beta generation," said Susan Austin, Ph.D., first author of the study and a postdoctoral research fellow at the Mayo Clinic.

The research team also studied tiny blood vessels in the brains of mice that had been genetically engineered to lack the eNOS enzyme. Those mice - which naturally have higher blood pressure and are prone to insulin resistance - had about a 50 percent reduction in nitrates and nitrites, indirectly reflecting nitric oxide production. The eNOS-deficient mice also showed higher levels of amyloid beta peptide in the brain, along with more APP and BACE1.

The study suggests that preserving a healthy blood vessel wall is important in ultimately preventing Alzheimer's disease, Katusic said. "On the cardiovascular side we've known for some time that preservation of healthy endothelium is critical to prevent major cardiovascular events. Now it seems this may have important implications for cognitive impairment."

The research could help explain, for instance, how exercise benefits cardiovascular health and the aging brain, Katusic said. Previous research has shown that exercise can delay or prevent cognitive impairment.

"There is a lot of literature showing that every time you exercise, you stimulate the endothelium to produce more nitric oxide," Katusic said. "What we have identified in this paper may help explain the reported (cognitive) benefit of exercise."

For more information: www.heart.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now